How Long Until Fat Dissolving Injections Work? The Week-by-Week Timeline in Myeongdong Seoul

Every figure above is the published Kind Global Clinic list price — identical for international and Korean patients, settled in KRW at zero foreign-card surcharge. Multi-session totals are always the published per-session figure × the session count fixed in writing at your assessment; no clinic can honestly promise a week-2 result or a one-session abdomen, and the written timeline is your protection against both.

The mechanism explains the wait

Deoxycholic-acid-class solutions are adipocytolytic: injected into subcutaneous fat, they disrupt adipocyte cell membranes within hours of contact. What follows is the slow part — a controlled local inflammatory response recruits macrophages that clear the released lipids and cellular debris over 2–6 weeks, and fibroblast activity remodels the zone afterward. That sequence is why the treated area swells for 3–7 days, feels firm or nodular for 2–4 weeks, and only then begins to look smaller. A zone that is puffy at day 3 and unchanged at week 2 is not failing; it is mid-process on the same curve the clinical trials documented.

What the randomized trials measured — and when they measured it

The pivotal REFINE-1 trial randomized 506 adults with submental fat to ATX-101 (deoxycholic acid injection) or placebo, allowing up to 6 treatment sessions at 4-week intervals — and assessed the primary outcome 12 weeks after the final treatment. 70.0% of ATX-101 patients versus 18.6% of placebo patients achieved at least a 1-grade improvement on the composite clinician-and-patient fat rating scale. Those two protocol numbers — 4-week intervals, week-12 assessment — are exactly the schedule Kind Global Clinic Myeongdong writes into every fat dissolving injection plan: the trial designers knew the biology would not show its full result any earlier.

The European phase III program reported the same shape of curve: a randomized, double-blind, placebo-controlled trial of ATX-101 at 1 mg/cm² and 2 mg/cm² found statistically significant submental fat reduction versus placebo, with patient-reported satisfaction improving in step with the measured reduction — and with transient injection-site swelling, numbness and firmness as the dominant side effects, resolving over the weeks that the clearance process runs. For durability, a long-term Asian-cohort follow-up of noninvasive body contouring in Taiwan documented maintained circumference reduction at follow-up beyond 1 year — consistent with the core physiology that adult fat cells destroyed in a treated zone are not replaced, so the contour holds while body weight stays stable.

1. Jones DH, et al. REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction. Dermatol Surg. 2016;42(1):38-49. doi:10.1097/DSS.0000000000000578 — 506 patients, up to 6 sessions at 4-week intervals, primary assessment 12 weeks after final treatment; 70.0% vs 18.6% composite 1-grade responder rate.
2. Ascher B, et al. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study. J Eur Acad Dermatol Venereol. 2014;28(12):1707-1715. doi:10.1111/jdv.12377 — European phase III; significant fat reduction at both 1 and 2 mg/cm² doses with transient injection-site effects.
3. Chang SL, et al. Long-term follow-up for noninvasive body contouring treatment in Asians. Lasers Med Sci. 2016;31(2):283-287. doi:10.1007/s10103-015-1852-0 — Taiwanese cohort; documents maintained contour reduction at long-term follow-up, Asian-skin durability evidence for nonsurgical fat reduction.